Juan Gu

PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis

Juan Gu, Zeping Wang, Raymond Reeves et al. · Oncogene · 2009 · 118 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +14

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents

Kai Xue, Juan Gu, Qunling Zhang et al. · Journal of Cancer Research and Clinical Oncology · 2015 · 88 citations · Full text

Medicine, Oncology, Pharmacology +16

Entinostat, a novel histone deacetylase inhibitor is active in B‐cell lymphoma and enhances the anti‐tumour activity of rituximab and chemotherapy agents

Sarah Frys, Zachary Simons, Qiang Hu et al. · British Journal of Haematology · 2015 · 48 citations · Full text

Medicine, Oncology, Pharmacology +13

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

Juan Gu, Anil Singh, Kai Xue et al. · Oncotarget · 2017 · 48 citations · Full text

Medicine, Cancer Biology, Oncology +17

The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti‐tumour activity of chemotherapy in rituximab‐resistant lymphoma

Juan Gu, Francisco J. Hernandez‐Ilizaliturri, Gregory P. Kaufman et al. · British Journal of Haematology · 2013 · 42 citations · Full text

Medicine, Oncology, Pharmacology +16